Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5403_Библиотеки_им_академика_М_И_Перельмана
.pdf
Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect
DOI: http://ITexLi.115104
agents like anthracycline analogs and others. Attaining the intended therapeutic
61
https://t.me/med1917
outcomes within the hypoxic region becomes unfeasible due to the combination of
reduced oxygen levels and increased distance from the nearest blood capillary. This
situation represents an unfavorable prognostic and predictive factor, as it contributes
to various aspects such as chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism, and
genomic instability. In all challenging circumstances, different reductase enzymes
are upregulated during hypoxia, effectively reducing aromatic azo (NN), nitro
(NO2), and quinone moieties. Based on this inherent conversion, several theranostics have been created, wherein the cleavage of the azo bond (NN) or reduction
of the nitro group (NO2) to amine (NH2) facilitates the self-immolative discharge
of active therapeutic components into the low-oxygen area of the solid tumor. Recent
advancements in hypoxia-responsive theranostics have been consolidated in Table
While diverse strategic theranostics have been documented, none have yet pro
gressed to the clinical trial stage. Further efforts are required to develop hypoxia-sensitive theranostics that may enhance clinical benefits and address existing healthcare
challenges.
Light-activated theranostics
.
.
To date, we have discussed numerous endogenous stimuli-responsive theranostics
that actively deliver chemotherapeutic agents to various cell types/cancers based
on the presence of specific stimulants. It is important to note that these stimulants
are also present in normal cells but in relatively lower quantities, thus ensuring that
the therapeutic agents are selectively released solely in the tumor region cannot be
guaranteed. External stimulants, such as light, have been utilized to trigger the release
of therapeutics, a process commonly referred to as “photo caging,” where drugs are
shielded or “caged.” UV or laser irradiation facilitates the controlled release of therapeutics in a spatially and temporally precise manner. Some critical examples of the
photo trigger theranostic in a consulate form are provided in Table
The utilization of photo-triggered activation of anticancer drugs represents a
.
unique and innovative strategy. By employing this approach, it becomes possible to
activate the therapeutic agent with a higher degree of precision specifically at the
intended target tumor site.
Theranostics Active ingredients In vitro cells In vivo/ex-vivo Re f.
OPV-Luminol Luminol & ROS HeLa HeLa cell tumor
10/11 SN-38/CA-4 MCF-7 — [67]
CMP-NCL-CA4
(1–5)
CMP-L-Rh Combretastatin A-4 Colon 26 cells SC colon 26 tumors
1(Biotin-taggedONB-CC)
,, CA-074 Inhibitors MDA-MB-231/MCF-10A — [71]
combretastatin A-4,
Pc-(L-CA4)
chlorambucil MDA-MB-231 cells — [70]
Colon 26 cells SC colon 26 tumors [68]
mice model
mice model
[66]
[69]
Table 3.
Information onphoto-triggered theranostics.
Smart Drug Delivery Systems – Futuristic Window in Cancer Therapy
62
https://t.me/med1917
. Recent cutting-edge strategies in cancer theranostics
The forefront of medical advancement includes the innovative idea of selfimmolative theranostics, in which the therapeutic substance undergoes a controlled
chemical reaction, causing its self-degradation under certain circumstances. This
characteristic is frequently harnessed to prompt the release of the therapeutic payload precisely at the disease site, thereby improving its effectiveness and reducing
unintended effects elsewhere. In the previously mentioned approaches, the primary
focus is on delivering chemotherapeutic agents to cancer cells or tumors. However,
these strategies have not yet been assessed for their effectiveness against multidrugresistant cancers/metastasis cancer. It’s crucial to note that multidrug-resistant
cancer remains one of the most lethal forms of cancer, with the highest mortality
rates. With a focus on addressing multidrug-resistant cancer, Kim et al. strategically
engineered prodrug (depicted in Figure ), which combines a protein phosphatase 2A (PP2A) inhibitor with a DNA damage chemotherapeutic agent linked
via a GSH-responsive labile linker [72]. In this context, the protein phosphatase 2A
(PP2A) inhibitor, demethyl cantharidin (DMC), inhibits PP2A activity. This inhibition leads to elevated MDM2 expression, subsequently triggering the reduction
of p53-p21 mediated G1/S checkpoint arrest, thereby diminishing the DNA repair
pathway. Conversely, 5-fluorouracil inhibits the growth of DNA in newly born cells. It
disrupts DNA synthesis and, to a lesser extent, hinders RNA formation by integrating
itself into RNA molecules, resulting in the generation of faulty RNA. Additionally,
fluorouracil hampers uracil riboside phosphorylase activity, impeding preexisting uracil’s utilization in RNA synthesis. The strategic prodrug is preferentially
Figure 11.
Example of recently reported cutting-edge cancer theranosic.
Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect
DOI: http://ITexLi.115104
localized in the mitochondria, where triphenyl phosphonium cation drives to localize
63
https://t.me/med1917
in the mitochondria. After cellular glutathione cleaves the vulnerable –S–S– bond,
DMC and 5-fluorouracil are activated, ultimately disrupting the usual mitochondrial functions in cancer cells. Prodrug exhibited greater anticancer efficacy in
PP2A over-expressed breast cancer cell line (4T1) and colon cancer cells HCT116
compared to PP2A unexpressed cancer cell line. This heightened anticancer effect
was accompanied by increased production of reactive oxygen species (ROS), resulting in DNA damage. Subsequently, mitochondrial swelling occurred, leading to the
rupture of the mitochondrial outer membrane and the release of the pro-apoptotic
protein cytochrome C. In the in vivo mouse model with HCT 116-inoculated mice, the
combination of drugs in prodrug significantly reduced tumor volume and size by
three times more compared to using DMC or 5-fluorouracil alone. This exemplifies
the effectiveness of combination therapy in combatting cancer.
By reprogramming mitochondrial metabolism, the cancer esterase-activated prodrug overcomes multidrug resistance activity, leading to delayed prodrug activation and enabling evasion of drug efflux mechanisms [73]. After esterase hydrolysis,
releasing of dichloroacetate (DCA) and doxorubicin leads to p21Waf1 upregulation,
reduction of PDH phosphorylation, and cleavage of caspase-3, and PARP-1 allows to
show high anticancer activity in multidrug resistance MCF-7. It effectively suppressed
tumor growth in the MCF/Dox xenograft mice model, with no indication of hepatotoxicity in the treated animals.
An additional theranostic prodrug, labeled as [74], is triggered by various
cellular reactive oxygen species (ROS) and has demonstrated its effectiveness in
combating metastatic cancer. Typically, cancer cells exhibit heightened levels of
multiple ROS, but a single ROS may not be adequate to activate the anticancer drug
within the theranostic platform. Therefore, a carbamate-linked theranostic labeled
as was developed, incorporating biotin-PEGylation. Following 15days of injecting
metastatic cervical cancer cell-bearing mice with doses dependent on the treatment, a
remarkable inhibition of tumor growth (99%) was observed, coupled with the depletion of HIF-1α, leading to a survival period of over 45days for the treated mice.
Another formidable aspect is tumor recurrence, wherein 90% of anticancer
medications fall short of providing the anticipated therapeutic effectiveness, resulting in increased mortality rates [75]. Ironically, recurrence is frequently triggered
by chemotherapy as a result of the accumulation of nuclear genomic mutations
throughout the treatment regimen. Antineoplastic agents that induce nuclear-DNA
damage, such as alkylating agents, are prevalent chemical mutagens and have been
associated with tumor recurrence. To address this ongoing challenge in cancer treatment, ciprofloxacin-conjugated (MT-CFX) (
Figure ) was employed to improve
mitochondrial targeting [76]. The payload release within the mitochondria triggers
oxidative damage to proteins, mitochondrial DNA (mtDNA), and lipids. A significant
preference for damaging mtDNA over nuclear DNA (nDNA) was observed in cancer
cells. It showed anticancer activity in various cancer cells namely, MDA-MB-231(IC50:
31.31μM), SW620 (IC50: 31.82μM), DU145 (IC50: 55.51μM), A549 (IC50: 23.77μM),
PC3 (IC
: 86.45μM) compared to the normal cells, BJ (IC50: 631.82μM), MCF10A
50
(IC50: ≥1000μM). The fluorophore-linked variant of , known as Bo-Mt-CFX, administered via intravenous injection (0.5mmol/kg) in an MDA-MB-231 xenograft mouse
model, resulted in more than a threefold reduction in both the tumor volume and size.
Hypoxia poses another challenge in overcoming multidrug resistance in tumors.
Kim et al. introduced theranostic (Figure ) in conjunction with photodynamic
therapy and chemotherapy to address this challenge [77]. The theranostic construct
Smart Drug Delivery Systems – Futuristic Window in Cancer Therapy
64
https://t.me/med1917
underwent reduction within the hypoxic tumor microenvironment, resulting in the
liberation of a near-infrared-emissive fluorophore and an active chemotherapeutic
drug. Consequently, during photodynamic therapy (PDT), theranostic aided
in eliminating normoxic tumor cells located in the superficial layer of the tumor.
Additionally, the activatable chemotherapy facilitated the eradication of hypoxic
tumor cells situated in the core of the tumors, thereby enhancing treatment efficacy
for solid tumors in mice. This double-aided approach introduces a new dimension in
cancer therapy, especially multidrug resistance cancer.
In this discussion, there is a notable focus on addressing multidrug resistance in
cancer therapy through diverse and sophisticated strategic approaches. These methods include the activation of reactive oxygen species (ROS) and the incorporation of
multidrug components. This approach integrates both the therapeutic and diagnostic
components, aiming to overcome resistance mechanisms exhibited by cancer cells
against multiple drugs. Through a combination of various therapeutic modalities
and diagnostic techniques, this approach seeks to enhance treatment efficacy while
providing insights into the resistance mechanisms at play, thereby enabling personalized and more effective cancer therapy.
. Conclusions and prospective outlook
In conclusion, the development and exploration of stimuli-responsive theranostics
(GSH, H2O2, H2S, pH, β-galactosidase, hypoxia) have brought significant advancements to the field of cancer treatment and diagnostic capabilities. The numerous
strategies and methodologies discussed herein reflect the tremendous potential of
these emerging technologies. As researchers continue to delve into the intricacies of
various stimuli-responsive platforms, there remains a wealth of opportunities and
potential for further exploration and development in this domain. Currently, optically modulated theranostics remain primarily of academic interest. Advancing these
to clinical trial phases requires generating additional data through high-throughput
assays, comprehensively exploring mechanisms, and collecting pharmacokinetic and
pharmacodynamic information.
Looking ahead, the prospective outlook for stimuli-responsive theranostics is
exceedingly promising. Continued research and development in this area hold the
key to addressing the existing limitations and challenges associated with traditional
cancer treatment modalities. By leveraging the dynamic nature of these responsive
systems, it is conceivable that refined and highly targeted therapeutic interventions
can be achieved, thereby maximizing efficacy while minimizing off-target effects and
potential toxicity. With a comprehensive understanding of the underlying mechanisms and a focused effort toward the development of novel and optimized therapeutic strategies, stimuli-responsive theranostics are poised to play a pivotal role in the
future of personalized and precision medicine.
Acknowledgements
SB thanks DST-SERB, India, for the research grant (CRG/2023/005905).
Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect
DOI: http://ITexLi.115104
65
https://t.me/med1917
Smart Drug Delivery Systems – Futuristic Window in Cancer Therapy
66
https://t.me/med1917
References
[1] Hanselmann RG, Welter C. Origin
of cancer: An information, energy, and
matter disease. Frontiers in Cell and
Developmental Biology. 2016;:121.
DOI:10.3389/fcell.2016.00121
[2] Cicenas J, Zalyte E,Bairoch A,
Gaudet P. Cancers. 2018;:63.
DOI:10.3390/cancers10030063
[3] Lammers T, Aime S, Hennink WE,
Storm G, Kiessling F. Theranostic
nanomedicine. Accounts of Chemical
Research. 2011;:1029-1038.
DOI:10.1021/ar200019c
[4] Fan Z, Fu PP, Yu H, Ray PC.
Theranostic nanomedicine for cancer
detection and treatment. Journal of Food
Drug Analysis. 2014;:3-17
[5] Sim AJ, Kaza E, Singer L,
Rosenberg SA. A review of the role
of MRI in diagnosis and treatment of
early-stage lung cancer. Clinical and
Translational Radiation Oncology.
2020; :16-22. DOI:10.1016/j.
ctro.2020.06.002
[9] Meyer MG, Hayenga J, Neumann T,
Katdare R, Presley C, Steinhauer D, et al.
The cell-CT 3D cell imaging technology
platform enables the detection of lung
cancer using the non-invasive LuCED
sputum test. Cancer Cytopathology.
2015;:512-523. DOI:10.1002/
cncy.21576
[10] Hapuarachchige S, Artemov D.
Theranostic pretargeting drug delivery
and imaging platforms in cancer
precision medicine. Frontiers in
Oncology. 2020;:1131. DOI:10.3389/
fonc.2020.01131
[11] Li X, Kim J, Yoon J, Chen X. Cancer-
associated, stimuli-driven, turn-on
theranostics for multimodality imaging
and therapy. Advanced Materials.
2017;:1606857. DOI:10.1002/
adma.201606857
[12] Biswas S, Rao CM. Epigenetics in
cancer: Fundamentals and beyond.
Pharmacology & Therapeutics.
2017;:118-134. DOI:10.1016/j.
pharmthera.2017.02.011
[6] Unterrainer V, Eze C, Ilhan H,
Marschner S, Roengvoraphoj O,
Schmidt-Hegemann NS, et al. Recent
advances of PET imaging in clinical
radiation oncology. Radiation Oncology.
2020;:88. DOI:10.1186/
s13014-020-01519-1
[7] Wang X, Yang M. The application
of ultrasound image in cancer
diagnosis. Journal of Healthcare
Engineering. 2021;:8619251.
DOI:10.1155/2021/8619251
[8] Woo Y, Chaurasiya S, O’Leary M,
Han E, Fong Y. Molecular Therapy
Oncolytics. 2021;:231-238.
DOI:10.1016/j.omto.2021.06.007
[13] Hanahan D, Weinberg RA. Hallmarks
of cancer: The next generation. Cell.
2011; :646-674. DOI:10.1016/j.
cell.2011.02.013
[14] Boneh A, Mandla S, Tenenhouse HS.
Phorbol myristate acetate activates
protein kinase C, stimulates the
phosphorylation of endogenous proteins
and inhibits phosphate transport in
mouse renal tubules. Biochimica et
Biophysica Acta (BBA)-Molecular
Cell Research. 1989;(3):308-316.
DOI:10.1016/0167-4889(89)90113-4
[15] Kim J, Yao F, Xiao Z, Sun Y, Ma L.
MicroRNAs and metastasis: Small RNAs
play big roles. Cancer and Metastasis
Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect
DOI: http://ITexLi.115104
Reviews. 2018;:5-15. DOI:10.1007/
67
https://t.me/med1917
s10555-017-9712-y
Nature Reviews Cancer. 2002;(10):750-
763. DOI:10.1038/nrc903
[16] Sporn MB, Roberts AB. Autocrine
growth factors and cancer. Nature.
1985;:745-747. DOI:10.1038/313745a0
[17] Kattan WE, Hancock JF. RAS
function in cancer cells: Translating
membrane biology and biochemistry into
new therapeutics. Biochemical Journal.
2020;:2893-2919. DOI:10.1042/
BCJ20190839
[18] Chen C, Liu TS, Zhao SC,
Yang WZ, Chen ZP, Yan Y. XIAP impairs
mitochondrial function during apoptosis
by regulating the Bcl-2 family in renal
cell carcinoma. Experimental and
Therapeutic Medicine. 2018;:4587-
4593. DOI:10.3892/etm.2018.5974
[19] Safa AR. Roles of c-FLIP in apoptosis,
necroptosis, and autophagy. Journal
of Carcinogenesis & Mutagenesis.
2013;Suppl. :003. DOI:10.4172/2157-
2518.S6-003
[20] Zhong L, Li Y, Xiong L, Wang W,
Wu M, Yuan T, et al. Small molecules
in targeted cancer therapy: Advances,
challenges, and future perspectives.
Signal Transduction and Targeted
Therapy. 2021;:201. DOI:10.1038/
s41392-021-00572-w
[21] Stavrovskaya AA. Cellular
mechanisms of multidrug resistance
of tumor cells. Biochemistry
(Moscow). 2000;:95-106.
DOI:0006-2979/00/6501-0095
[22] Kaur N, Popli P, Tiwary N, Swami R.
Small molecules as cancer targeting
ligands: Shifting the paradigm. Journal
of Controlled Release. 2023;:417-433.
DOI:10.1016/j.jconrel.2023.01.032
[24] Kennedy L, Sandhu JK, Harper ME,
Cuperlovic-Culf M. Role of glutathione
in cancer: From mechanisms to
therapies. Biomolecules. 2020;:1429.
DOI:10.3390/biom10101429
[25] Váradi A, Sarkadi B. Multidrug
resistance-associated proteins: Export
pumps for conjugates with glutathione,
glucuronate or sulfate. BioFactors.
2003;:103-114. DOI:10.1002/
biof.5520170111
[26] Santra S, Kaittanis C,
Santiesteban OJ, Perez JM. Cell-specific,
activatable, and theranostic prodrug
for dual-targeted cancer imaging
and therapy. Journal of the American
Chemical Society. 2011;:16680-16688.
DOI:10.1021/ja207463b
[27] Bhuniya S, Maiti S, Kim EJ, Lee H,
Sessler JL, Hong KS, et al. An activatable
theranostic for targeted cancer therapy
and imaging. Angewandte Chemie.
2014;(17):4558-4563
[28] Lee MH, Kim JY, Han JH,
Bhuniya S, Sessler JL, Kang C, et al.
Direct fluorescence monitoring of
the delivery and cellular uptake of a
cancer-targeted RGD peptide-appended
naphthalimide theragnostic prodrug.
Journal of the American Chemical
Society. 2012;(30):12668-12674.
DOI:10.1021/ja303998y
[29] Maiti S, Park N, Han JH, Jeon HM,
Lee JH, Bhuniya S, et al. Gemcitabine–
coumarin–biotin conjugates: A targetspecific theranostic anticancer prodrug.
Journal of the American Chemical
Society. 2013;(11):4567-4572.
DOI:10.1021/ja401350x
[23] Allen TM. Ligand-targeted
therapeutics in anticancer therapy.
[30] Yang Z, Lee JH, Jeon HM,
Han JH, Park N, He Y, et al. Folate-based
Smart Drug Delivery Systems – Futuristic Window in Cancer Therapy
68
https://t.me/med1917
near-infrared fluorescent theranostic
gemcitabine delivery. Journal of
the American Chemical Society.
2013;:11657-11662. DOI:10.1021/
ja405372k
[31] Wu X, Sun X, Guo Z, Tang J,
Shen Y, James TD, et al. In vivo and in situ
tracking cancer chemotherapy by highly
photostable NIR fluorescent theranostic
prodrug. Journal of the American
Chemical Society. 2014;:3579-3588.
DOI:10.1021/ja412380j
[32] Bhuniya S, Lee MH, Jeon HM,
Han JH, Lee JH, Park N, et al. A
fluorescence off–on reporter for
real-time monitoring of gemcitabine
delivery to the cancer cells. Chemical
Communications. 2013;:7141-7143.
DOI: 10.1039/C3CC42653J
[33] Jeon HM, Le HT, Kim TW, Kim JS.
A biotin-guided fluorescent-peptide
drug delivery system for cancer
treatment. Chemical Communications.
2014;:7690-7693. DOI:10.1039/
C4CC02878C
[34] Wu J, Huang R, Wang C, Liu W,
Wang J, Weng X, et al. Thiol-inducible
direct fluorescence monitoring of
drug release. Organic & Biomolecular
Chemistry. 2013;:580-585.
DOI:10.1039/c2ob26680f
[35] Dutta D, Alex SM, Bobba KN,
Maiti KK, Bhuniya S. New insight into
a cancer theranostic probe: Efficient
cell-specific delivery of SN-38 guided
by biotinylated poly (vinyl alcohol).
ACS Applied Materials & Interfaces.
2016;(49):33430-33438. DOI:10.1021/
acsami.6b10580
[36] Lennicke C, Rahn J, Lichtenfels R,
Wessjohann LA, Seliger B. Hydrogen
peroxide–production, fate, and role
in redox signaling of tumor cells.
Cell Communication and Signaling.
2015;(1):1-9. DOI:10.1186/
s12964-015-0118-6
[37] Lisanti MP, Martinez-Outschoorn UE,
Lin Z, Pavlides S, Whitaker-Menezes D,
Pestell RG, et al. Hydrogen peroxide
fuels aging, inflammation, cancer
metabolism and metastasis: The seed
andsoil also needs “fertilizer”. Cell Cycle.
2011;(15):2440-2449. DOI:10.4161/
cc.10.15.16870
[38] Kim EJ, Bhuniya S, Lee H, Kim HM,
Cheong C, Maiti S, et al. An activatable
prodrug for the treatment of metastatic
tumors. Journal of the American
Chemical Society. 2014;:13888-13894.
DOI:10.1021/ja5077684
[39] Kumar R, Han J, Lim HJ, Ren WX,
Lim JY, Kim JH, et al. Mitochondrial
induced and self-monitored intrinsic
apoptosis by antitumor theranostic
prodrug: In vivo imaging and precise
cancer treatment. Journal of the American
Chemical Society. 2014;(51):17836-
17843. DOI:10.1021/ja510421q
[40] Redy-Keisar O, Ferber S, Satchi-
Fainaro R, Shabat D. NIR fluorogenic
dye as a modular platform for prodrug
assembly: Real-time in vivo monitoring
of drug release. ChemMedChem.
2015;:999-1007. DOI:10.1002/
cmdc.201500060
[41] Renga B. Hydrogen sulfide
generation in mammals: The molecular
biology of cystathionine-β-synthase
(CBS) and cystathionine-γ-lyase
(CSE). Inflammation & AllergyDrug Targets. 2011;(2):85-91.
DOI:10.2174/187152811794776286
[42] Papapetropoulos A, Pyriochou A,
Altaany Z, Yang G, Marazioti A, Zhou Z,
et al. Hydrogen sulfide is an endogenous
stimulator of angiogenesis. Proceedings
of the National Academy of Sciences.
2009;:21972-21977. DOI:10.1073/
pnas.0908047106
Fluorescence Guided Activatable Cancer Theranostics: Its Development and Prospect
DOI: http://ITexLi.115104
[43] Szabo C, Hellmich MR. Endogenously
69
https://t.me/med1917
produced hydrogen sulfide supports
tumor cell growth and proliferation.
Cell Cycle. 2013;(18):2915-2916.
DOI:10.4161/cc.26064
prodrug for real-time drug release
monitoring and targeted cancer
therapy. Chemical Communications.
2014;:11852-11855. DOI:10.1039/
C4CC05008H
[44] Velusamy N, Binoy A, Bobba KN,
Nedungadi D, Mishra N, Bhuniya S. A
bioorthogonal fluorescent probe for
mitochondrial hydrogen sulfide: New
strategy for cancer cell labeling. Chemical
Communications. 2017;(62):8802-
8805. DOI:10.1039/c7cc05339h
[45] Bobba KN, Binoy A, Koo S,
Nedungadi D, Podder A, Sharma A, et al.
Direct readout protonophore induced
selective uncoupling and dysfunction
of individual mitochondria within
cancer cells. Chemical Communications.
2019;:6429-6432. DOI:10.1039/
c9cc01483g
[46] Bobba KN, Saranya G, Sujai PT,
Joseph MM, Velusamy N, Podder A,
et al. Endogenous H2S-assisted cancercell-specific activation of theranostics
with emission readout. ACS Applied
Bio Materials. 2019;(3):1322-1330.
DOI:10.1021/acsabm.9b00019
[50] Li SY, Liu LH, Rong L,
Qiu WX, Jia HZ, Li B, et al. A dualFRET-based versatile prodrug for
real-time drug release monitoring and
in situ therapeutic efficacy evaluation.
Advanced Functional Materials.
2015;(47):7317-7326. DOI:10.1002/
adfm.201503262
[51] Lee MH, Kim EJ, Lee H, Park SY,
Hong KS, Kim JS, et al. Acid-triggered
release of doxorubicin from a
hydrazone-linked Gd
3+
−texaphyrin
conjugate. Chemical Communications.
2016;(69):10551-10554. DOI:10.1039/
C6CC05673C
[52] Yao M, Ma X, Zhang X, Shi L,
Liu T, Liang X, et al. Lectin-mediated
pH-sensitive doxorubicin prodrug for
pre-targeted chemotherapy of colorectal
cancer with enhanced efficacy and
reduced side effects. Theranostics.
2019;(3):747. DOI:10.7150/thno.29989
[47] Maiti M, Yoon SA, Cha Y,
Athul KK, Bhuniya S, Lee MH. Cellspecific activation of gemcitabine
by endogenous H2S stimulation
and tracking through simultaneous
fluorescence turn-on. Chemical
Communications. 2021;:9614-9617.
DOI:10.1039/d1cc00118c
[48] Shi B, Ren N, Gu L, Xu G, Wang R,
Zhu T, et al. Theranostic nanoplatform
with hydrogen sulfide activatable NIR
responsiveness for imaging-guided
on-demand drug release. Angewandte
Chemie. 2019;:16982-16986.
DOI:10.1002/ange.201909883
[49] Li SY, Liu LH, Jia HZ, Qiu WX,
Rong L, Cheng H, et al. A pH-responsive
[53] Siriwibool S, Kaekratoke N,
Chansaenpak K, Siwawannapong K,
Panajapo P, Sagarik K, et al. Nearinfrared fluorescent pH responsive
probe for targeted photodynamic
cancer therapy. Scientific Reports.
2020;(1):1283. DOI:10.1038/
s41598-020-58239-5
[54] Liu L, Mason RP. Imaging
β-galactosidase activity in human tumor
xenografts and transgenic mice using a
chemiluminescent substrate. PLoS One.
2010;(8):e12024. DOI:10.1371/journal.
pone.0012024
[55] Maiti M, Kikuchi K, Athul KK,
Kaur A, Bhuniya S. β-Galactosidaseactivated theranostic for hepatic
Smart Drug Delivery Systems – Futuristic Window in Cancer Therapy
70
https://t.me/med1917
carcinoma therapy and imaging.
Chemical Communications.
2022;(44):6413-5416. DOI:10.1039/
d2cc01825j
[56] Almammadov T, Elmazoglu Z,
Atakan G, Kepil D, Aykent G, Kolemen S,
et al. Locked and loaded: β-galactosidase
activated photodynamic therapy agent
enables selective imaging and targeted
treatment of glioblastoma multiforme
cancer cells. ACS Applied Bio Materials.
2022;(9):4284-4293. DOI:10.1021/
acsabm.2c00484
[57] Sharma A, Kim EJ, Shi H, Lee JY,
Chung BG, Kim JS. Development of
a theranostic prodrug for colon
cancer therapy by combining
ligand-targeted delivery and enzymestimulated activation. Biomaterials.
2018;:145-151. DOI:10.1016/j.
biomaterials.2017.11.019
[58] Semenza GL. Expression of
hypoxia-inducible factor 1: Mechanisms
and consequences. Biochemical
Pharmacology. 2000;(1):47-53.
DOI:10.1016/s0006-2952(99)00292-0
[59] Kumar R, Kim EJ, Han J, Lee H,
Shin WS, Kim HM, et al. Hypoxiadirected and activated theranostic
agent: Imaging and treatment of solid
tumor. Biomaterials. 2016;:119-128.
DOI:10.1016/j.biomaterials.2016.07.010
[60] Zhou Y, Maiti M, Sharma A,
Won M, Yu L, Miao LX, et al. Azo-based
small molecular hypoxia responsive
theranostic for tumor-specific imaging
and therapy. Journal of Controlled
Release. 2018;:14-22. DOI:10.1016/j.
jconrel.2018.08.036
[61] Liu W, Liu H, Peng X, Zhou G,
Liu D, Li S, et al. Hypoxia-activated
anticancer prodrug for bioimaging,
tracking drug release, and anticancer
application. Bioconjugate Chemistry.
2018;(10):3332-3343. DOI:10.1021/acs.
bioconjchem.8b00511
[62] Koo S, Bobba KN, Cho MY, Park HS,
Won M, Velusamy N, et al. Molecular
theranostic agent with programmed
activation for hypoxic tumors. ACS
Applied Bio Materials. 2019;(10):4648-
4655. DOI:10.1021/acsabm.9b00722
[63] Zhao YQ , Biswas S, Chen Q ,
Jia M, Zhou Y, Bhuniya S. Direct readout
hypoxia tumor suppression in vivo
through NIR-theranostic activation. ACS
Applied Bio Materials. 2021;(7):5686-
5694. DOI:10.1021/acsabm.1c00467
[64] Ho TC, Chan AH, Ganesan A. Thirty
years of HDAC inhibitors: 2020 insight
and hindsight. Journal of Medicinal
Chemistry. 2020;(21):12460-12484.
DOI:10.1021/acs.jmedchem.0c00830
[65] Kim JH, Verwilst P, Won M, Lee J,
Sessler JL, Han J, et al. A small molecule
strategy for targeting cancer stem cells
in hypoxic microenvironments and
preventing tumorigenesis. Journal
of the American Chemical Society.
2021;(35):14115-14124. DOI:10.1021/
jacs.1c03875
[66] Yuan H, Chong H, Wang B, Zhu C,
Liu L, Yang Q , et al. Chemical moleculeinduced light-activated system for
anticancer and antifungal activities.
Journal of the American Chemical
Society. 2012;(32):13184-13187.
DOI:10.1021/ja304986t
[67] Hossion AM, Bio M, Nkepang G,
Awuah SG, You Y. Visible light-controlled
release of anticancer drug through
double activation of prodrug.
ACS Medicinal Chemistry Letters.
2013;(1):124-127. DOI:10.1021/
ml3003617
[68] Bio M, Rajaputra P,Nkepang G,
Awuah SG, Hossion AM, You Y.
Соседние файлы в папке Библиотека им академика М.И. Перельмана